Are trefoil factors oncogenic?

Trends in Endocrinology and Metabolism

Volumn 19, Issue 2, 2008, Pages 74-81

  Perry, Jo K ^a   Kannan, Nagarajan ^a   Grandison, Prudence M ^a   Mitchell, Murray D ^a   Lobie, Peter E ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; HUMAN GROWTH HORMONE; PLASMA PROTEIN; SOMATOMEDIN C; TREFOIL PEPTIDE;

ANCHORAGE INDEPENDENT GROWTH; ANGIOGENESIS; ANOIKIS; APOPTOSIS; BREAST CANCER; CANCER CELL; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL STUDY; COLON CANCER; DISEASE FREE SURVIVAL; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN STRUCTURE; REVIEW; SOLID TUMOR; STOMACH CANCER; STOMACH CARCINOMA;

ANIMALS; DISEASE; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; HUMANS; MODELS, BIOLOGICAL; ONCOGENES; PEPTIDES; PROGNOSIS;

EID: 39849100276     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2007.10.003     Document Type: Review

References (79)

1. Thim L., and May F.E. Structure of mammalian trefoil factors and functional insights. Cell. Mol. Life Sci. 62 (2005) 2956-2973
2. Taupin D., and Podolsky D.K. Trefoil factors: initiators of mucosal healing. Nat. Rev. Mol. Cell Biol. 4 (2003) 721-732
3. Regalo G., et al. Trefoil factors: from ulceration to neoplasia. Cell. Mol. Life Sci. 62 (2005) 2910-2915
4. Madsen J., et al. Tissue localization of human trefoil factor 1, 2, and 3. J. Histochem. Cytochem. 55 (2007) 505-513
5. Baus-Loncar M., and Giraud A.S. Multiple regulatory pathways for trefoil factor (TFF) genes. Cell. Mol. Life Sci. 62 (2005) 2921-2931
6. Emami S., et al. Trefoil factor family (TFF) peptides and cancer progression. Peptides 25 (2004) 885-898
7. Hoffmann W. Trefoil factors TFF (trefoil factor family) peptide-triggered signals promoting mucosal restitution. Cell. Mol. Life Sci. 62 (2005) 2932-2938
8. Ren L., et al. Estrogenic effects of nonylphenol on pS2, ER and MUC1 gene expression in human breast cancer cells-MCF-7. Chem. Biol. Interact. 104 (1997) 55-64
9. Maras M., et al. Estrogen-like properties of fluorotelomer alcohols as revealed by mcf-7 breast cancer cell proliferation. Environ. Health Perspect. 114 (2006) 100-105
10. Olsen C.M., et al. Effects of the environmental oestrogens bisphenol A, tetrachlorobisphenol A, tetrabromobisphenol A, 4-hydroxybiphenyl and 4,4′-dihydroxybiphenyl on oestrogen receptor binding, cell proliferation and regulation of oestrogen sensitive proteins in the human breast cancer cell line MCF-7. Pharmacol. Toxicol. 92 (2003) 180-188
11. May F.E., and Westley B.R. Expression of human intestinal trefoil factor in malignant cells and its regulation by oestrogen in breast cancer cells. J. Pathol. 182 (1997) 404-413
12. Johnson M.D., et al. Oestrogenic activity of tamoxifen and its metabolites on gene regulation and cell proliferation in MCF-7 breast cancer cells. Br. J. Cancer 59 (1989) 727-738
13. Kannan, N. et al. (2007) Mediation of tamoxifen resistance in mammary carcinoma cells by trefoil factor-3. American Association for Cancer Research Annual Meeting Abstracts, 1632
14. Soubeyran I., et al. Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases. Br. J. Cancer 73 (1996) 735-743
15. Weaver C.A., et al. Regulation of pS2 gene expression by affinity labeling and reversibly binding estrogens and antiestrogens: comparison of effects on the native gene and on pS2-chloramphenicol acetyltransferase fusion genes transfected into MCF-7 human breast cancer cells. Mol. Endocrinol. 2 (1988) 936-945
16. Kuske B., et al. Endocrine therapy resistance can be associated with high estrogen receptor {alpha} (ERα) expression and reduced ERα phosphorylation in breast cancer models. Endocr. Relat. Cancer 13 (2006) 1121-1133
17. Osborne C.K., et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J. Natl. Cancer Inst. 87 (1995) 746-750
18. Jackerott M., et al. Trefoil factors are expressed in human and rat endocrine pancreas: differential regulation by growth hormone. Endocrinology 147 (2006) 5752-5759
19. Xu X.Q., et al. Gene expression profiling to identify oncogenic determinants of autocrine human growth hormone in human mammary carcinoma. J. Biol. Chem. 280 (2005) 23987-24003
20. Wilson K.S., et al. Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. Am. J. Pathol. 161 (2002) 1171-1185
21. Taupin D., et al. The trefoil gene family are coordinately expressed immediate-early genes: EGF receptor- and MAP kinase-dependent interregulation. J. Clin. Invest. 103 (1999) R31-R38
22. Bossenmeyer-Pourie C., et al. The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. J. Cell Biol. 157 (2002) 761-770
23. Chan M.W., et al. Anti-sense trefoil factor family-3 (intestinal trefoil factor) inhibits cell growth and induces chemosensitivity to adriamycin in human gastric cancer cells. Life Sci. 76 (2005) 2581-2592
24. Yio X., et al. Trefoil factor family-1 mutations enhance gastric cancer cell invasion through distinct signaling pathways. Gastroenterology 130 (2006) 1696-1706
25. Hoosein N.M., et al. Growth stimulatory effect of pancreatic spasmolytic polypeptide on cultured colon and breast tumor cells. FEBS Lett. 247 (1989) 303-306
26. Yio X., et al. Trefoil factor family-3 is associated with aggressive behavior of colon cancer cells. Clin. Exp. Metastasis 22 (2005) 157-165
27. Rodrigues S., et al. Induction of the adenoma-carcinoma progression and Cdc25A-B phosphatases by the trefoil factor TFF1 in human colon epithelial cells. Oncogene 25 (2006) 6628-6636
28. Rivat C., et al. Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3) and vascular endothelial growth factor-mediated cellular invasion and tumor growth. Cancer Res. 65 (2005) 195-202
29. Chan V.Y., et al. Intestinal trefoil factor promotes invasion in non-tumorigenic Rat-2 fibroblast cell. Regul. Pept. 127 (2005) 87-94
30. Graness A., et al. Protein kinase C and ERK activation are required for TFF-peptide-stimulated bronchial epithelial cell migration and tumor necrosis factor-alpha-induced interleukin-6 (IL-6) and IL-8 secretion. J. Biol. Chem. 277 (2002) 18440-18446
31. Rodrigues S., et al. Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling. FASEB J. 17 (2003) 7-16
32. Dhar D.K., et al. Expression of trefoil factor family members correlates with patient prognosis and neoangiogenesis. Clin. Cancer Res. 11 (2005) 6472-6478
33. Dhanasekaran S.M., et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412 (2001) 822-826
34. Henry J.A., et al. Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy. Br. J. Cancer 61 (1990) 32-38
35. May F.E., and Westley B.R. Trefoil proteins: their role in normal and malignant cells. J. Pathol. 183 (1997) 4-7
36. West M., et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 11462-11467
37. Speiser P., et al. pS2 protein status fails to be an independent prognostic factor in an average breast cancer population. Anticancer Res. 14 (1994) 2125-2130
38. Gillesby B.E., and Zacharewski T.R. pS2 (TFF1) levels in human breast cancer tumor samples: correlation with clinical and histological prognostic markers. Breast Cancer Res. Treat. 56 (1999) 253-265
39. Tozlu S., et al. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr. Relat. Cancer 13 (2006) 1109-1120
40. Foekens J.A., et al. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Br. J. Cancer 70 (1994) 1217-1223
41. Carr M., et al. Determination of oestrogen responsiveness of breast cancer by competitive reverse transcription-polymerase chain reaction. Br. J. Cancer 72 (1995) 1427-1434
42. Doane A.S., et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25 (2006) 3994-4008
43. Miller L.D., et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 13550-13555
44. Mikhitarian K., et al. An innovative microarray strategy identities informative molecular markers for the detection of micrometastatic breast cancer. Clin. Cancer Res. 11 (2005) 3697-3704
45. Weigelt B., et al. Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers. Br. J. Cancer 90 (2004) 1531-1537
46. Smid M., et al. Genes associated with breast cancer metastatic to bone. J. Clin. Oncol. 24 (2006) 2261-2267
47. May F.E., et al. Expression and motogenic activity of TFF2 in human breast cancer cells. Peptides 25 (2004) 865-872
48. Bosma A.J., et al. Detection of circulating breast tumor cells by differential expression of marker genes. Clin. Cancer Res. 8 (2002) 1871-1877
49. Weigelt B., et al. Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br. J. Cancer 88 (2003) 1091-1094
50. Lacroix M. Significance, detection and markers of disseminated breast cancer cells. Endocr. Relat. Cancer 13 (2006) 1033-1067
51. Ren J.L., et al. Molecular forms of trefoil factor 1 in normal gastric mucosa and its expression in normal and abnormal gastric tissues. World J. Gastroenterol. 12 (2006) 7361-7364
52. Milne A.N., et al. Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers. Mod. Pathol. 19 (2006) 564-572
53. Hippo Y., et al. Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer Res. 61 (2001) 889-895
54. Sonoda H., et al. Detection of lymph node micrometastasis in pN0 early gastric cancer: efficacy of duplex RT-PCR with MUC2 and TFF1 in mucosal cancer. Oncol. Rep. 16 (2006) 411-416
55. Suarez C., et al. Prognostic significance of cytosolic pS2 protein content in gastric cancer. Int. J. Biol. Markers 16 (2001) 37-44
56. Mori K., et al. Highly specific marker genes for detecting minimal gastric cancer cells in cytology negative peritoneal washings. Biochem. Biophys. Res. Commun. 313 (2004) 931-937
57. Houghton J., et al. Gastric cancer originating from bone marrow-derived cells. Science 306 (2004) 1568-1571
58. Park W.S., et al. Somatic mutations of the trefoil factor family 1 gene in gastric cancer. Gastroenterology 119 (2000) 691-698
59. Welter C., et al. Expression pattern of breast-cancer-associated protein pS2/BCEI in colorectal tumors. Int. J. Cancer 56 (1994) 52-55
60. Hackel C., et al. The pS2 protein in colorectal carcinomas and metastases. Pathol. Res. Pract. 194 (1998) 171-176
61. Tuna B., et al. PS2 and HSP70 expression in rectal adenocarcinomas: an immunohistochemical investigation of 45 cases. Appl. Immunohistochem. Mol. Morphol. 14 (2006) 31-36
62. Taupin D., et al. Conserved expression of intestinal trefoil factor in the human colonic adenoma-carcinoma sequence. Lab. Invest. 75 (1996) 25-32
63. Welsh J.B., et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 61 (2001) 5974-5978
64. Luo J., et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res. 61 (2001) 4683-4688
65. Vestergaard E.M., et al. Plasma levels of trefoil factors are increased in patients with advanced prostate cancer. Clin. Cancer Res. 12 (2006) 807-812
66. Higashiyama M., et al. Estimation of serum level of pS2 protein in patients with lung adenocarcinoma. Anticancer Res. 16 (1996) 2351-2355
67. Higashiyama M., et al. Prognostic significance of pS2 protein expression in pulmonary adenocarcinoma. Eur. J. Cancer 30A (1994) 792-797
68. Prasad N.B., et al. Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res. 65 (2005) 1619-1626
69. Collier J.D., et al. Immunolocalization of pS2, a putative growth factor, in pancreatic carcinoma. J. Gastroenterol. Hepatol. 10 (1995) 396-400
70. Khoury T., et al. Expression of intestinal trefoil factor (TFF-3) in hepatocellular carcinoma. Int. J. Gastrointest. Cancer 35 (2005) 171-177
71. Okada H., et al. Frequent trefoil factor 3 (TFF3) overexpression and promoter hypomethylation in mouse and human hepatocellular carcinomas. Int. J. Oncol. 26 (2005) 369-377
72. Kraus S., et al. MUC1 mucin and trefoil factor 1 protein expression in renal cell carcinoma: correlation with prognosis. Hum. Pathol. 33 (2002) 60-67
73. Wysocki S.J., et al. Detection of pS2 messenger RNA in gynecological cancers. Cancer Res. 50 (1990) 1800-1802
74. Speiser P., et al. pS2 and PAI-1 in ovarian cancer: correlation to pathohistological parameters. Anticancer Res. 17 (1997) 679-683
75. Luqmani Y.A., et al. An immunohistochemical survey of pS2 expression in human epithelial cancers. Int. J. Cancer 50 (1992) 302-304
76. Koshiyama M., et al. Expression of pS2 protein in endometrial carcinomas: correlation with clinicopathologic features and sex steroid receptor status. Int. J. Cancer 74 (1997) 237-244
77. Callagy G.M. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin. Cancer Res. 12 (2006) 2468-2475
78. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer 1 (2001) 118-129
79. Siu L.S., et al. TFF1 is membrane-associated in breast carcinoma cell line MCF-7. Peptides 25 (2004) 745-753